Sort   by:  
 Page size 
UnknownRenal vascular lesions in childhood-onset lupus nephritis.

Background

This study aimed to determine the clinical significance of renal vascular lesions (RVLs) in childhood-onset lupus nephritis (cLN).

Methods

We retrospectively reviewed all children with biopsy-proven cLN between 2004-2020 to evaluate the prevalence of RVLs on kidney biopsy a...
S-EPMC11584461 | biostudies-literature
UnknownCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment ...
S-EPMC11560846 | biostudies-literature
UnknownRisk factors for loss of residual renal function in children treated with chronic peritoneal dialysis.
In dialyzed patients, preservation of residual renal function is associated with better survival, lower morbidity, and greater quality of life. To analyze the evolution of residual diuresis over time, we prospectively monitored urine output in 401 pediatric patients in the global IPPN registry who c...
S-EPMC4558567 | biostudies-literature
UnknownAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.

Background

Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherap...
S-EPMC7616360 | biostudies-literature
UnknownDuration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.

Background

Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy rema...
S-EPMC7616389 | biostudies-literature
UnknownCurrent and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.
At least 5% of cancer diagnoses are attributed to a causal pathogenic or likely pathogenic germline genetic variant (hereditary cancer syndrome-HCS). These individuals are burdened with lifelong surveillance monitoring organs for a wide spectrum of cancers. This is associated with substantial uncert...
S-EPMC10577078 | biostudies-literature
UnknownGenome-wide germline correlates of the epigenetic landscape of prostate cancer.
Oncogenesis is driven by germline, environmental and stochastic factors. It is unknown how these interact to produce the molecular phenotypes of tumors. We therefore quantified the influence of germline polymorphisms on the somatic epigenome of 589 localized prostate tumors. Predisposition risk loci...
S-EPMC7418214 | biostudies-literature
UnknownPatterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously receive...
S-EPMC10262978 | biostudies-literature
UnknownNew Approaches to SCLC Therapy: From the Laboratory to the Clinic.
The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the cl...
S-EPMC7263769 | biostudies-literature
UnknownDivergent mutational processes distinguish hypoxic and normoxic tumours.
Many primary tumours have low levels of molecular oxygen (hypoxia), and hypoxic tumours respond poorly to therapy. Pan-cancer molecular hallmarks of tumour hypoxia remain poorly understood, with limited comprehension of its associations with specific mutational processes, non-coding driver genes and...
S-EPMC7002770 | biostudies-literature
Sort   by:  
 Page size